Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 4
1974 2
1976 3
1977 2
1978 2
1979 4
1980 6
1981 3
1982 5
1983 13
1984 16
1985 22
1986 11
1987 19
1988 21
1989 20
1990 28
1991 27
1992 40
1993 28
1994 25
1995 38
1996 32
1997 34
1998 29
1999 25
2000 37
2001 52
2002 70
2003 59
2004 56
2005 72
2006 110
2007 90
2008 118
2009 113
2010 165
2011 208
2012 266
2013 209
2014 232
2015 277
2016 256
2017 343
2018 440
2019 469
2020 582
2021 659
2022 840
2023 779
2024 857
2025 1041
2026 478

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,372 results

Results by year

Filters applied: . Clear all
Page 1
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. Jurczak W, et al. Among authors: su w. J Clin Oncol. 2026 Feb 20;44(6):466-475. doi: 10.1200/JCO-25-02380. Epub 2025 Dec 9. J Clin Oncol. 2026. PMID: 41363773 Free PMC article. Clinical Trial.
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W; SACHI Study Group. Lu S, et al. Among authors: su w. Lancet. 2026 Jan 24;407(10526):375-387. doi: 10.1016/S0140-6736(25)01811-2. Epub 2026 Jan 13. Lancet. 2026. PMID: 41544643 Clinical Trial.
8,372 results